morphine 6-nicotinate: RN given refers to (5alpha,6alpha)-isomer
ID Source | ID |
---|---|
PubMed CID | 5488579 |
MeSH ID | M0100275 |
Synonym |
---|
morphine 6-nicotinate |
unii-819768139g |
75533-60-7 |
6-nicotinoylmorphine |
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5alpha,6alpha)-, 6-(3-pyridinecarboxylate) |
819768139g , |
6-mononicotioylmorphine |
morphin-6-nicotinat |
J457.075H , |
6-mononicotinoylmorphine |
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, 6-(3-pyridinecarboxylate) |
morphine, 6-nicotinate |
DTXSID00996994 |
3-hydroxy-17-methyl-7,8-didehydro-4,5-epoxymorphinan-6-yl pyridine-3-carboxylate |
Q27269232 |
[(4r,4ar,7s,7ar,12bs)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] pyridine-3-carboxylate |
Excerpt | Reference | Relevance |
---|---|---|
" The rate of absorption differs between patients and governs the overall pharmacokinetic profile of the compound." | ( Pharmacokinetics of intramuscular nicomorphine and its metabolites in man. Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Nijhuis, GM; Vree, TB, 1991) | 0.28 |
Excerpt | Reference | Relevance |
---|---|---|
" The rate of absorption differs between patients and governs the overall pharmacokinetic profile of the compound." | ( Pharmacokinetics of intramuscular nicomorphine and its metabolites in man. Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Nijhuis, GM; Vree, TB, 1991) | 0.28 |
"29), suggesting it is directly related to the absorption rate of nicomorphine." | ( The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients. Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Vree, TB, 1995) | 0.29 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (42.86) | 18.7374 |
1990's | 4 (57.14) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.21) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (28.57%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (71.43%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |